ClinicalTrials.gg
Status unknownNCT01172405Updated Jul 29, 2010

Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache

A Phase 3 interventional study of Ibuprofen plus caffeine and Ibuprofen in Headache, sponsored by Mantecorp Industria Quimica e Farmaceutica Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-07-29.

Sponsored by Mantecorp Industria Quimica e Farmaceutica Ltd. (part of Hypera Pharma) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2010), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Based on established therapeutic effect of ibuprofen in the treatment of headache attacks, and the action of caffeine in promoting better results when combined with treatments of first choice in the treatment of headache, this study is designed to:

  • evaluate the efficacy of therapy with ibuprofen + caffeine in headache patients compared to ibuprofen alone;
  • evaluate the tolerability of the association ibuprofen + caffeine compared to ibuprofen alone.

The hypothesis is that the association is superior to treatment with ibuprofen alone in terms of efficacy, while maintaining good tolerability.

02

Conditions studied

  • Headache

Keywords

  • Headache
  • Migraine
  • Ibuprofen
  • Caffeine
03

In context

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

This study's planned enrollment of 144 is above the median of 65 across 560 interventional studies indexed under Headache.

Browse Headache studies →

Lead sponsor

Mantecorp Industria Quimica e Farmaceutica Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ability to read, understand and sign the IC;
  • Patients with symptoms of frequent episodic tension headache, mild to moderate;
  • Patients with symptoms of migraine with or without aura, of mild to moderate intensity;
  • Patients who have had between two and five headache attacks in the last 30 days;
  • Patients who accept the condition of ingesting less than three cups of coffee per day and / or reduce the intake of any beverage that contains caffeine;
  • Patients who accept the condition not to drink any beverage that contains caffeine for 24 hours after drug administration.
  • Patients able to understand and maintain the clinical protocol.
  • Patients who started or changed prophylactic treatment for headache 30 days before inclusion.
  • Female patients of childbearing age must agree to undergo pregnancy testing through urine.

Exclusion criteria

Exclusion Criteria:

  • Patients in whom headache began after 50 years of age;
  • Patients with strong or disabling headaches;
  • Patients with chronic daily headaches lasting up to 72 h or with cluster headaches not responsive to common analgesics;
  • Patients with headaches occurring in 15 or more days per month;
  • Patients with secondary headaches;
  • Patients who overuse analgesics (acetylsalicylic acid up to 300 mg / day) or NSAIDs;
  • Known to components of both formulations of the drug test as the comparison;
  • Known hepatic or renal diseases;
  • Patients who are pregnant or intend to become pregnant or lactating;
  • Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart diseases, hematological diseases, convulsive disorders, diseases, renal failure, severe infections, hormonal disorders, pulmonary disorders and peptic diseases;
  • History of alcoholism or substance abuse.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Ibuprofen + Caffeine

    72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.

    Drug: Ibuprofen plus caffeine

  • Active comparator
    Ibuprofen

    72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.

    Drug: Ibuprofen

Interventions

  • DrugIbuprofen plus caffeine

    Drug pages: Ibuprofen · Caffeine

    One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.

  • One or two tablets of ibuprofen 400 mg when presenting headache.

    Also known as: DALSY

06

What researchers measure

Primary outcomes

  1. Efficacy of study treatment compared with control to relieve headache symptoms.

    The evaluation of efficacy will be determined based on comparison of the intensity of headache before and after initiation of treatment, using the Functional Disabling Scale. The opinion of the investigator will be established based on the Likert scale and duration of symptoms after the treatment will be checked as a measure of comparison between treatments in the study.

    Time frame: 4 weeks

Secondary outcomes

  1. Tolerability of study treatment compared with control to relieve headache symptoms.

    Tolerability will be assessed by the investigator through the number of adverse events definitely related to study medication. This relationship will be defined by applying the Naranjo algorithm.

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2010
First posted
Jul 29, 2010
Start
Oct 2010
Primary completionEst.
Oct 2012
CompletionEst.
Oct 2012
Last update
Jul 29, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01172405
First posted
Jul 29, 2010
Start date
Oct 2010
Primary completion
Oct 2012 (estimated)
Completion
Oct 2012 (estimated)
Last update
Jul 29, 2010

Study contacts

Claudia Domingues
Contact
cdomingues@mantecorp.com
+551151885237

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Caffeine

Start the discussion